Across TCGA pan-cancer cohorts, CLTRN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLTRN data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLTRN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLTRN expression acts as an unfavorable survival marker.
HNSC, LGG, and UCEC are the cancer types where CLTRN Mutation most reproducibly stratifies survival.